IDEXX Laboratories, Inc. (IDXX)
Should You Hold IDEXX Stock in Your Portfolio for Now?
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
IDEXX Laboratories Q3: Weak End-Market Demand Continues
I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth.
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68.
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket
IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.
Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago.
IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow
IDEXX Laboratories trimmed its annual revenue forecast for the third time on Thursday, as the animal health diagnostic equipment maker sees fewer visits to veterinary clinics from pet owners.
Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDXX Gears Up for Q3 Earnings: What to Expect From the Stock?
IDEXX Laboratories' third-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
